Compare Gilead Sciences, Inc. (GILD) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Western Union Co — how do they compare? Gilead Sciences, Inc. trades at $133.65 (market cap $163.51B), while Western Union Co trades at $8.31 (market cap $2.51B). The key difference: Gilead Sciences, Inc. is far larger — about 65.1× Western Union Co's market cap, and Western Union Co pays the higher dividend (11.69%). Which is the better fit depends on your goals.
| GILD | WU | |
|---|---|---|
Market Cap | $163.51B | $2.51B |
Sector | Health | Technology |
52-Week High | $155.80 | $10.28 |
52-Week Low | $108.22 | $7.04 |
Enterprise Value | $178.05B | $2.21B |
Dividend Yield | 2.49% | 11.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Western Union (WU) trades at $8.275, up 5.01% in the last session, with a bullish technical signal from moving averages. The stock shows strong profitability with a 10.88% net income margin and 47.66% ROE, though recent Q1 2026 earnings missed expectations. Valuation ratios appear attractive with a P/E of 5.91 and P/S of 0.64. Recent developments include a partnership with Total Wireless for fee-free money transfers and progress on the Intermex acquisition, enhancing digital reach.
Outlook is mixed: low valuations and dividend yield near 5.8% offer value, but declining revenue from $4.5B in 2022 to $4.0B projected for 2026 poses growth concerns. Risks include high debt levels and competitive pressures. Analysts are cautious with a consensus hold rating and $7.50 price target below the current price, indicating limited upside potential amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
